Taiwan · Delayed Price · Currency is TWD Orient Pharma Statistics
Total Valuation
Orient Pharma has a market cap or net worth of TWD 5.75 billion. The enterprise value is 5.32 billion.
| Market Cap | 5.75B |
| Enterprise Value | 5.32B |
Important Dates
The next estimated earnings date is Thursday, August 13, 2026.
| Earnings Date | Aug 13, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Orient Pharma has 223.04 million shares outstanding. The number of shares has increased by 3.32% in one year.
| Current Share Class | 223.04M |
| Shares Outstanding | 223.04M |
| Shares Change (YoY) | +3.32% |
| Shares Change (QoQ) | +4.64% |
| Owned by Insiders (%) | 1.03% |
| Owned by Institutions (%) | n/a |
| Float | 37.41M |
Valuation Ratios
The trailing PE ratio is 28.52.
| PE Ratio | 28.52 |
| Forward PE | n/a |
| PS Ratio | 4.11 |
| PB Ratio | 2.24 |
| P/TBV Ratio | 2.68 |
| P/FCF Ratio | 17.76 |
| P/OCF Ratio | 15.99 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 13.47, with an EV/FCF ratio of 16.43.
| EV / Earnings | 25.54 |
| EV / Sales | 3.80 |
| EV / EBITDA | 13.47 |
| EV / EBIT | 20.39 |
| EV / FCF | 16.43 |
Financial Position
The company has a current ratio of 6.73, with a Debt / Equity ratio of 0.08.
| Current Ratio | 6.73 |
| Quick Ratio | 4.77 |
| Debt / Equity | 0.08 |
| Debt / EBITDA | 0.50 |
| Debt / FCF | 0.60 |
| Interest Coverage | 33.01 |
Financial Efficiency
Return on equity (ROE) is 9.58% and return on invested capital (ROIC) is 10.44%.
| Return on Equity (ROE) | 9.58% |
| Return on Assets (ROA) | 5.98% |
| Return on Invested Capital (ROIC) | 10.44% |
| Return on Capital Employed (ROCE) | 9.49% |
| Weighted Average Cost of Capital (WACC) | 4.93% |
| Revenue Per Employee | 8.09M |
| Profits Per Employee | 1.20M |
| Employee Count | 173 |
| Asset Turnover | 0.51 |
| Inventory Turnover | 2.03 |
Taxes
In the past 12 months, Orient Pharma has paid 36.21 million in taxes.
| Income Tax | 36.21M |
| Effective Tax Rate | 14.80% |
Stock Price Statistics
The stock price has decreased by -9.47% in the last 52 weeks. The beta is 0.13, so Orient Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.13 |
| 52-Week Price Change | -9.47% |
| 50-Day Moving Average | 25.63 |
| 200-Day Moving Average | 27.73 |
| Relative Strength Index (RSI) | 52.80 |
| Average Volume (20 Days) | 341,572 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Orient Pharma had revenue of TWD 1.40 billion and earned 208.44 million in profits. Earnings per share was 0.90.
| Revenue | 1.40B |
| Gross Profit | 790.72M |
| Operating Income | 261.06M |
| Pretax Income | 244.65M |
| Net Income | 208.44M |
| EBITDA | 375.51M |
| EBIT | 261.06M |
| Earnings Per Share (EPS) | 0.90 |
Balance Sheet
The company has 627.40 million in cash and 195.95 million in debt, with a net cash position of 431.45 million or 1.93 per share.
| Cash & Cash Equivalents | 627.40M |
| Total Debt | 195.95M |
| Net Cash | 431.45M |
| Net Cash Per Share | 1.93 |
| Equity (Book Value) | 2.56B |
| Book Value Per Share | 11.49 |
| Working Capital | 1.07B |
Cash Flow
In the last 12 months, operating cash flow was 359.86 million and capital expenditures -35.82 million, giving a free cash flow of 324.04 million.
| Operating Cash Flow | 359.86M |
| Capital Expenditures | -35.82M |
| Depreciation & Amortization | 114.45M |
| Net Borrowing | -350.54M |
| Free Cash Flow | 324.04M |
| FCF Per Share | 1.45 |
Margins
Gross margin is 56.46%, with operating and profit margins of 18.64% and 14.88%.
| Gross Margin | 56.46% |
| Operating Margin | 18.64% |
| Pretax Margin | 17.47% |
| Profit Margin | 14.88% |
| EBITDA Margin | 26.81% |
| EBIT Margin | 18.64% |
| FCF Margin | 23.14% |
Dividends & Yields
Orient Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -3.32% |
| Shareholder Yield | -3.32% |
| Earnings Yield | 3.62% |
| FCF Yield | 5.63% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on May 23, 2016. It was a reverse split with a ratio of 0.6500936135.
| Last Split Date | May 23, 2016 |
| Split Type | Reverse |
| Split Ratio | 0.6500936135 |
Scores
Orient Pharma has an Altman Z-Score of 12.26 and a Piotroski F-Score of 7.
| Altman Z-Score | 12.26 |
| Piotroski F-Score | 7 |